Back to top

pharmaceuticals: Archive

Kinjel Shah

Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ

The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.

GSK AZN MRK PFE RHHBY JNJ

Zacks Equity Research

Sage Therapeutics' Depression Drug Fails in Study, Stock Down

Sage Therapeutics' (SAGE) phase III study on pipeline candidate SAGE-217 for the treatment of major depressive disorder fails to meet the primary endpoint.

ANIK ALKS SAGE VTGN

Zacks Equity Research

AstraZeneca's Lynparza Gets China Nod in First-Line Setting

AstraZeneca's (AZN) Lynparza receives approval in China for first-line maintenance treatment of advanced ovarian cancer with BRCA-mutation.

GSK AZN RHHBY MRK

Zacks Equity Research

Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV

Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.

GSK PFE JNJ GILD

Zacks Equity Research

Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD

The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.

GSK MRK PFE BMY

Zacks Equity Research

J&J Stock Witnesses Volatility in '19: What to Expect in 2020

Here we discuss the ups and downs of J&J's (JNJ) stock this year.

JNJ ABBV MRK RHHBY

Zacks Equity Research

Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up

Aurinia's (AUPH) lupus candidate, voclosporin, met primary endpoint of renal response rate in a late-stage study. An NDA is expected in the first half of 2020.

AZN RHHBY BIIB AUPH

Zacks Equity Research

Immunomedics Resubmits Application for Breast Cancer Drug

Immunomedics (IMMU) resubmits BLA to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer, who have received at least two prior therapies.

AZN RHHBY IMMU CLVS

Zacks Equity Research

AstraZeneca Sells Schizophrenia Drug Rights in US and Canada

AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.

AZN JNJ AGN ALKS

Zacks Equity Research

Bristol-Myers' Reblozyl to be Reviewed by FDA Committee

Bristol-Myers (BMY) and Acceleron Pharma Inc.'s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDA's Oncologic Drugs Advisory Committee.

GSK MRK BMY XLRN

Zacks Equity Research

Roche's Tecentriq-Chemo Combo Gets FDA Nod in First-Line NSCLC

Roche (RHHBY) obtains FDA approval for Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic NSCLC.

AZN BMY RHHBY MRK

Zacks Equity Research

J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders

J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.

JNJ ENDP TEVA MNK

Zacks Equity Research

Moving Average Crossover Alert: ANI Pharmaceuticals

ANI Pharmaceuticals could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

ANIP

Zacks Equity Research

Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised)

Pfizer (PFE)/Astellas' Xtandi gets approval in China to treat metastatic castration-resistant prostate cancer (CRPC).

BMY MRK RHHBY PFE

Zacks Equity Research

Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US

Mylan (MYL) launches Ogivri, a biosimilar of Roche's blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States.

RHHBY PFE TEVA MYL

Zacks Equity Research

Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer

Merck's (MRK) sBLA for Keytruda gets FDA's priority review status to treat certain patients with high-risk, non-muscle invasive bladder cancer.

GSK PFE MRK AMGN

Zacks Equity Research

X4 Pharmaceuticals Enters Oversold Territory

X4 Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

XFOR

Kinjel Shah

Large-Cap Pharmaceuticals Industry Prospects Bright for 2020

The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.

RHHBY PFE MRK GSK BMY

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for December 3rd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 3rd

UFAB OTIC IRWD CHRS

Zacks Equity Research

AstraZeneca's (AZN) Imfinzi Gets FDA Priority Tag for SCLC

AstraZeneca's (AZN) Imfinzi, if approved for extensive-stage small cell lung cancer, can cater to a broader lung cancer patient population, which can bring in additional sales.

MRK AZN BMY PFE

Zacks Equity Research

The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab

The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab

BABA LLY MRK CHTR SCHW

Zacks Equity Research

Catalyst Focuses on Firdapse Label Expansion Amid Competition

Catalyst (CPRX) focuses on the development of Firdapse for additional indications.

CPRX IRWD JAZZ FENC

Zacks Equity Research

Here's Why Merck's (MRK) Shares Are Up This Year

Merck's (MRK) shares are up 11.7% this year so far on strong performance and positive regulatory updates on its PD-1 inhibitor Keytruda.

MRK AZN PFE AMGN

Zacks Equity Research

Esperion's Promising Drugs Under Review, Funds a Concern

Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize the launch.

MRK SNY REGN ESPR

Christopher Vargas

3 Stocks for Value Investors to Buy as Market Reaches New High

The stock market closed at a record high today as the DJIA rose over 42 points and the S&P 500 gained 0.4%.

BAC PNC JPM C SAH AGN ABBV COST